Evidence mapPaperPMID 40422797Full record

ReviewMarine drugs2025

Marine-Derived Compounds Combined with Nanoparticles: A Focus on the Biomedical and Pharmaceutical Sector.

Laura M Teixeira, Catarina P Reis, Rita Pacheco

Abstract readReview
In one paragraph

Review in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Antidiabetic Potential of Sea UrchinCurrent issues in molecular biology · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Laura M TeixeiraDepartamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, Portugal.ORCID 0009-0004-6359-6945
Catarina P ReisInstitute for Medicines (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisboa, Portugal.ORCID 0000-0002-1046-4031
Rita PachecoCentro de Química Estrutural, Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, Portugal.ORCID 0000-0001-5192-3006

Funding

Fundação para a Ciência e Tecnologia (FCT) LA/P/0056/2020 (https://doi.org/10.54499/LA/P/0056/2020).Fundação para a Ciência e Tecnologia (FCT) UIDB/00100/2020 (https://doi.org/10.54499/UIDB/00100/2020) and UIDP/00100/2020 (https://doi.org/10.54499/UIDP/00100/2020)Fundação para a Ciência e Tecnologia (FCT) UIDB/04138/2020, UIDP/04138/2020, UIDB/00645/2020 (https://doi. org/10.54499/UIDB/00645/2020) and UIDP/00645/2020 (https://doi.org/10.54499/UIDP/00645/ 2020).Instituto Politécnico de Lisboa (IPL) IPL/IDI&CA2024/SeaCoats_ISEL
6 · The paper itself

Abstract

The ocean is an extraordinary natural source of a wide range of bioactive compounds. These compounds, including proteins, phenolics, polysaccharides, pigments, vitamins, and fatty acids, possess unique biological properties that are increasingly being explored in the field of nanotechnology across diverse sectors. Among marine-derived nanoparticles, promising applications have emerged in the biomedical and pharmaceutical fields, particularly metallic nanoparticles and polysaccharide-based drug delivery systems. This review provides a unique perspective on the integration of two research areas: the exploration of marine bioresources as bioactive compounds sources with nanotechnological methodologies to develop sustainable, safe, stable and functional marine-derived NPs. It highlights recent advancements in the green synthesis of MNPs and the formulation of drug delivery systems using marine polysaccharides. This review also describes the recent trends over the past ten years and discusses the major challenges and limitations associated with these approaches, including variability in biological sources, batch-to-batch inconsistency, mechanistic uncertainties, and difficulties in reproducibility and scalability. Furthermore, it emphasizes the need for standardized protocols and the integration of life cycle assessments (LCA) to evaluate environmental and economic viability for effective translating marine-derives nanoparticles from research to clinical applications.

Indexed as

Aquatic OrganismsBiological ProductsNanoparticlesAnimalsDrug Delivery SystemsGreen Chemistry TechnologyHumansNanotechnologyPolysaccharidesBiological ProductsPolysaccharidesdrug delivery systemsgreen synthesismarine bioactive compoundsmarine polysaccharidesnanoparticles

Identifiers

PMID40422797
PMCPMC12113654

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.